Vanguard Group
RNTX

Vanguard Group’s Rein Therapeutics RNTX Stock Holding History

Vanguard Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.35M Sell
1,165,807
-2,600
-0.2% -$3.58K ﹤0.01% 3695
2025
Q3 		$1.34M Buy
1,168,407
+284,300
+32% +$361K ﹤0.01% 3700
2025
Q2 		$1.24M Buy
884,107
+167,319
+23% +$301K ﹤0.01% 3684
2025
Q1 		$1.27M Buy
716,788
+291,794
+69% +$612K ﹤0.01% 3639
2024
Q4 		$977K Sell
424,994
-7,207
-2% -$21.8K ﹤0.01% 3772
2024
Q3 		$1.53M Sell
432,201
-73,952
-15% -$198K ﹤0.01% 3640
2024
Q2 		$1.4M Buy
506,153
+465,839
+1,156% +$1.91M ﹤0.01% 3679
2024
Q1 		$267K Hold
40,314
– – ﹤0.01% 4128
2023
Q4 		$123K Buy
40,314
+380
+1% +$741 ﹤0.01% 4277
2023
Q3 		$60.7K Sell
39,934
-539
-1% -$915 ﹤0.01% 4388
2023
Q2 		$72.4K Sell
40,473
-18,626
-32% -$28.7K ﹤0.01% 4417
2023
Q1 		$73.3K Sell
59,099
-71,216
-55% -$153K ﹤0.01% 4428
2022
Q4 		$309K Buy
130,315
+60
+0% +$202 ﹤0.01% 4215
2022
Q3 		$539K Sell
130,255
-24,406
-16% -$103K ﹤0.01% 4192
2022
Q2 		$804K Hold
154,661
– – ﹤0.01% 4155
2022
Q1 		$1.58M Sell
154,661
-16,645
-10% -$151K ﹤0.01% 4053
2021
Q4 		$1.93M Sell
171,306
-943
-0.5% -$14.6K ﹤0.01% 4051
2021
Q3 		$3.51M Buy
172,249
+217
+0.1% +$4.75K ﹤0.01% 3844
2021
Q2 		$4.3M Sell
172,032
-10,765
-6% -$269K ﹤0.01% 3672
2021
Q1 		$5.23M Buy
182,797
+160,586
+723% +$5.5M ﹤0.01% 3509
2020
Q4 		$462K Buy
22,211
+9,896
+80% +$247K ﹤0.01% 3968
2020
Q3 		$318K Buy
12,315
+1,099
+10% +$25.9K ﹤0.01% 3893
2020
Q2 		$265K Hold
11,216
– – ﹤0.01% 3887
2020
Q1 		$74K Sell
11,216
-404
-3% -$4.87K ﹤0.01% 3974
2019
Q4 		$133K Hold
11,620
– – ﹤0.01% 3983
2019
Q3 		$156K Sell
11,620
-5,030
-30% -$69.6K ﹤0.01% 3987
2019
Q2 		$240K Buy
16,650
+12,045
+262% +$316K ﹤0.01% 3947
2019
Q1 		$180K Buy
4,605
+269
+6% +$8.38K ﹤0.01% 3943
2018
Q4 		$73K Sell
4,336
-485
-10% -$19.5K ﹤0.01% 4035
2018
Q3 		$265K Buy
4,821
+356
+8% +$23.9K ﹤0.01% 3965
2018
Q2 		$484K Sell
4,465
-120
-3% -$13.6K ﹤0.01% 3827
2018
Q1 		$745K Buy
4,585
+641
+16% +$114K ﹤0.01% 3716
2017
Q4 		$831K Buy
3,944
+1,077
+38% +$258K ﹤0.01% 3651
2017
Q3 		$767K Buy
2,867
+2,367
+473% +$594K ﹤0.01% 3660
2017
Q2 		$111K Buy
+500
New +$110K ﹤0.01% 3981

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Vanguard Group's RNTX Position: Q4 2025 in Review

Vanguard Group reduced its Rein Therapeutics (RNTX) stake by 0.22% in Q4 2025, selling an estimated $3.58K and leaving 1,165,807 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

Vanguard Group first reported a position in RNTX in Q2 2017 and has held it in 35 quarters since. The position peaked at $5.23M in Q1 2021. 48 funds tracked by Wall St. Rank hold RNTX as of Q4 2025.

  • Vanguard Group held 1,165,807 shares of Rein Therapeutics worth $1.35M as of Q4 2025.
  • Vanguard Group sold 2,600 Rein Therapeutics shares in Q4 2025, an estimated $3.58K.
  • Rein Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3695 holding.
  • Vanguard Group first reported a position in Rein Therapeutics in Q2 2017 and has held it in 35 quarters since.
  • Vanguard Group's Rein Therapeutics position peaked at $5.23M in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.